- Home
- ATLC vs MLYS Comparison
ATLC vs MLYS Comparison
Compare ATLC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- MLYS
- Stock Information
- Founded
- ATLC 1996
- MLYS 2019
- Country
- ATLC United States
- MLYS United States
- Employees
- ATLC N/A
- MLYS N/A
- Industry
- ATLC Finance: Consumer Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- MLYS Health Care
- Exchange
- ATLC Nasdaq
- MLYS Nasdaq
- Market Cap
- ATLC 900.3M
- MLYS 890.6M
- IPO Year
- ATLC 1999
- MLYS 2023
- Fundamental
- Price
- ATLC $72.60
- MLYS $37.42
- Analyst Decision
- ATLC Buy
- MLYS Strong Buy
- Analyst Count
- ATLC 7
- MLYS 6
- Target Price
- ATLC $76.29
- MLYS $42.60
- AVG Volume (30 Days)
- ATLC 44.2K
- MLYS 2.6M
- Earning Date
- ATLC 11-06-2025
- MLYS 11-10-2025
- Dividend Yield
- ATLC N/A
- MLYS N/A
- EPS Growth
- ATLC 35.13
- MLYS N/A
- EPS
- ATLC 5.69
- MLYS N/A
- Revenue
- ATLC $457,158,000.00
- MLYS N/A
- Revenue This Year
- ATLC $293.56
- MLYS N/A
- Revenue Next Year
- ATLC $12.64
- MLYS N/A
- P/E Ratio
- ATLC $12.79
- MLYS N/A
- Revenue Growth
- ATLC 26.20
- MLYS N/A
- 52 Week Low
- ATLC $31.10
- MLYS $8.24
- 52 Week High
- ATLC $78.91
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- ATLC 68.07
- MLYS 83.46
- Support Level
- ATLC $66.55
- MLYS $34.59
- Resistance Level
- ATLC $78.91
- MLYS $39.20
- Average True Range (ATR)
- ATLC 2.51
- MLYS 2.76
- MACD
- ATLC 0.30
- MLYS 1.02
- Stochastic Oscillator
- ATLC 55.44
- MLYS 92.66
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.